The focus was on Hybrid Closed-Loop (HCL), Advanced Hybrid Closed-Loop (AHCL) and Full Closed-Loop (FCL) systems. These systems, also known as artificial pancreases, combine continuous glucose measurement with automatic insulin delivery and adjust insulin administration in real time.
The study shows that AID systems increase the time in the target range and improve the time with elevated glucose levels as well as the HbA1c value. AHCL systems increased the time in the target area by an average of 24%. Further studies are needed to better assess the effect.
DZD researcher Prof. Dr. Michael Roden from the German Diabetes Center (DDZ) emphasizes the importance of the study for clinical decision-making and therapy selection.
